JP2013538808A5 - - Google Patents

Download PDF

Info

Publication number
JP2013538808A5
JP2013538808A5 JP2013526580A JP2013526580A JP2013538808A5 JP 2013538808 A5 JP2013538808 A5 JP 2013538808A5 JP 2013526580 A JP2013526580 A JP 2013526580A JP 2013526580 A JP2013526580 A JP 2013526580A JP 2013538808 A5 JP2013538808 A5 JP 2013538808A5
Authority
JP
Japan
Prior art keywords
phenyl
thiazol
ureido
methyl
heterocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013526580A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013538808A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2011/053810 external-priority patent/WO2012029032A2/en
Publication of JP2013538808A publication Critical patent/JP2013538808A/ja
Publication of JP2013538808A5 publication Critical patent/JP2013538808A5/ja
Pending legal-status Critical Current

Links

JP2013526580A 2010-09-03 2011-08-31 Dgat1阻害剤としての複素環式化合物 Pending JP2013538808A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37976010P 2010-09-03 2010-09-03
US61/379,760 2010-09-03
PCT/IB2011/053810 WO2012029032A2 (en) 2010-09-03 2011-08-31 Heterocyclic compounds as dgat1 inhibitors

Publications (2)

Publication Number Publication Date
JP2013538808A JP2013538808A (ja) 2013-10-17
JP2013538808A5 true JP2013538808A5 (enExample) 2014-10-09

Family

ID=44802328

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013526580A Pending JP2013538808A (ja) 2010-09-03 2011-08-31 Dgat1阻害剤としての複素環式化合物

Country Status (14)

Country Link
US (1) US20130158075A1 (enExample)
EP (1) EP2611783A2 (enExample)
JP (1) JP2013538808A (enExample)
KR (1) KR20130114122A (enExample)
CN (1) CN103228633A (enExample)
AR (1) AR084474A1 (enExample)
AU (1) AU2011297669A1 (enExample)
BR (1) BR112013005210A2 (enExample)
CA (1) CA2810130A1 (enExample)
IN (1) IN2013MN00581A (enExample)
MX (1) MX2013002462A (enExample)
RU (1) RU2013114932A (enExample)
TW (1) TW201213314A (enExample)
WO (1) WO2012029032A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107074839A (zh) * 2013-08-29 2017-08-18 贝勒医学院 用于治疗代谢和体重相关的病症的组合物和方法
JP6749344B2 (ja) * 2015-02-13 2020-09-02 アジエンダ・オスペダリエラ・ウニベルシタリア・セネーゼ 治療剤としてのヒトヘリカーゼddx3阻害剤
CN109053624B (zh) * 2018-09-26 2022-11-22 河南师范大学 具有ido抑制活性的噻唑类衍生化合物、制备方法及其用途
WO2024145662A1 (en) * 2022-12-30 2024-07-04 Altay Therapeutics, Inc. 2-substituted thiazole and benzothiazole compositions and methods as dux4 inhibitors

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4812470A (en) 1982-02-27 1989-03-14 Beecham Group P.L.C. Antibacterial monic acid derivatives
IT1201523B (it) 1982-05-18 1989-02-02 Angeli Inst Spa Eterociclilfenilfomramidine,processi per la loro preparazione e loro uso farmaceutico
WO2001066099A2 (en) * 2000-03-06 2001-09-13 Astrazeneca Ab Use of quinazoline derivatives as angiogenesis inhibitors
US7419984B2 (en) * 2002-10-17 2008-09-02 Cell Therapeutics, Inc. Pyrimidines and uses thereof
WO2004113331A1 (en) 2003-06-20 2004-12-29 Galderma Research & Development, S.N.C. Novel compounds that modulate pparϝ type receptors, and use thereof in cosmetic or pharmaceutical compositions
JP2009505962A (ja) 2005-07-29 2009-02-12 バイエル・ヘルスケア・エルエルシー 肥満を治療するためのビフェニルアミノ酸誘導体の製造および使用
JP2007045752A (ja) * 2005-08-10 2007-02-22 Takeda Chem Ind Ltd 5員芳香族複素環誘導体、その製造法および用途
US20080064717A1 (en) * 2006-05-19 2008-03-13 Rajesh Iyengar Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme
WO2008069313A1 (ja) 2006-12-07 2008-06-12 Japan Tobacco Inc. ピロリジン化合物の製造方法
JP2008255024A (ja) * 2007-04-02 2008-10-23 Banyu Pharmaceut Co Ltd ビアリールアミン誘導体
JP2010526781A (ja) * 2007-04-30 2010-08-05 アボット・ラボラトリーズ ジアシルグリセロールo−アシル転移酵素1型酵素の阻害剤
BRPI0814818A2 (pt) * 2007-07-09 2019-09-10 Astrazeneca Ab composto, uso de um composto, métodos para produzir um efeito anti-proliferativo e um efeito inibitório de mtor quinase em uma animal de sangue quente, método para tratar doenças, e, composição farmacêutica
WO2009011285A1 (ja) * 2007-07-13 2009-01-22 Taisho Pharmaceutical Co., Ltd. ヘテロアリールベンゼン化合物
US8119658B2 (en) 2007-10-01 2012-02-21 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
TW201010700A (en) * 2008-08-25 2010-03-16 Piramal Lifesciences Ltd Diacylglycerol acyltransferase inhibitors
EP2346853A2 (en) * 2008-11-19 2011-07-27 Schering Corporation Inhibitors of diacylglycerol acyltransferase
US20120172369A1 (en) * 2009-09-14 2012-07-05 Ting Pauline C Inhibitors of diacylglycerol acyltransferase

Similar Documents

Publication Publication Date Title
JP2013506637A5 (enExample)
JP5498786B2 (ja) 新規なマロン酸スルホンアミド誘導体およびその医薬用途
JP2003534336A5 (enExample)
JP2006526656A5 (enExample)
RU2383524C2 (ru) Гексафторизопропанол-замещенные производные простых эфиров
RU2013113118A (ru) Гетероарилметиламиды
DE1283831T1 (de) Inhibitoren der 11-beta-hydroxy-steroid-dehydrogenase des typs 1
CA2785948A1 (en) Inhibitors of diacylglycerol acyl transferase
CA2568766A1 (en) Crth2 receptor ligands for medicinal uses
RU2009102516A (ru) Ингибиторы протеинтирозинфосфатазы человека и способы их использования
JP2007519692A5 (enExample)
AU5731099A (en) Substituted oxazoles and thiazoles derivatives as hppar gamma and hppar alpha activators
JP2013538808A5 (enExample)
JP2009114185A (ja) Ppar活性化化合物及びこれを含有する医薬組成物
JP2010540462A5 (enExample)
MX2011009821A (es) Derivados de isotiazolo pirimidinadiona como moduladores del trpa1.
RU2001126559A (ru) Активаторы глюкокиназы
MX2007007101A (es) Derivados de oxadiazol como inhibidores de acil coa:diacilglicerol aciltransferasa.
NZ552061A (en) CETP Inhibitors
JP2010501587A5 (enExample)
CA2797920A1 (en) Heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes
RU2004104951A (ru) Замещенные пиперазиновые соединения и их применение в качестве ингибиторов окисления жирных кислот
AU2004215672B2 (en) 3-methyl-2- (3- (2-phenyl-oxazol-4-ylmethoxy)-cyclohexanecarbonyl-amino butyric acid derivatives and related compounds as PPAR modulators for the treatment of type 2 diabetes and atherosclerosis
ES2505190T3 (es) Derivados de piperidina como antagosistas del receptor nk3
RU2013114932A (ru) Гетероциклические соединения в качестве ингибиторов dgat1